Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Descending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55648-0633-01 55648-0633 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
55648-0633-02 55648-0633 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
55648-0632-01 55648-0632 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
55648-0186-01 55648-0186 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous March 2, 2013 In Use
55567-0150-06 55567-0150 Flutamide Flutamide Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 1, 2015 Nov. 30, 2015 No Longer Used
55567-0150-13 55567-0150 Flutamide Flutamide Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 1, 2015 Nov. 30, 2015 No Longer Used
55567-0150-25 55567-0150 Flutamide Flutamide Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 1, 2015 Nov. 30, 2015 No Longer Used
55566-8403-01 55566-8403 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 In Use
55566-8401-00 55566-8401 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 March 31, 2015 No Longer Used
55566-8401-01 55566-8401 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 March 31, 2015 No Longer Used
55566-8401-02 55566-8401 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist May 24, 2013 March 31, 2015 No Longer Used
55566-8303-01 55566-8303 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 In Use
55566-8301-00 55566-8301 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 March 31, 2015 No Longer Used
55566-8301-01 55566-8301 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist March 2, 2009 March 31, 2015 No Longer Used
55566-8301-02 55566-8301 Degarelix Firmagon Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist May 24, 2013 March 31, 2015 No Longer Used
55566-1050-01 55566-1050 Nadofaragene firadenovec-vncg ADSTILADRIN 300000000000.0 {VP}/mL Immunotherapy Gene Therapy IFN⍺2b Intravesical July 1, 2023 In Use
55513-0956-01 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
55513-0955-01 55513-0955 Panitumumab Vectibix 200.0 mg/10mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 Feb. 28, 2010 No Longer Used
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
55513-0924-01 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0924-10 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0924-91 55513-0924 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0823-01 55513-0823 Epoetin alfa Epogen Ancillary Therapy Erythropoiesis-Stimulating Agent March 3, 1997 July 31, 2010 No Longer Used
55513-0823-10 55513-0823 Epoetin alfa Epogen Ancillary Therapy Erythropoiesis-Stimulating Agent March 3, 1997 July 31, 2010 No Longer Used
55513-0730-01 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Nov. 18, 2010 In Use
55513-0710-01 55513-0710 Denosumab Prolia 60.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous June 5, 2010 In Use
55513-0710-21 55513-0710 Denosumab Prolia 60.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous March 5, 2024 In Use
55513-0546-01 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0546-10 55513-0546 Filgrastim Neupogen 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous April 7, 1997 In Use
55513-0530-01 55513-0530 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 19, 1997 In Use
55513-0530-10 55513-0530 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 19, 1997 In Use
55513-0520-01 55513-0520 Palifermin Kepivance Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF Dec. 15, 2004 Dec. 15, 2009 No Longer Used
55513-0520-06 55513-0520 Palifermin Kepivance Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF Dec. 15, 2004 Dec. 15, 2009 No Longer Used
55513-0512-60 55513-0512 Sotorasib LUMAKRAS 240.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral June 27, 2024 In Use
55513-0504-50 55513-0504 Sotorasib LUMAKRAS 320.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral Feb. 2, 2023 In Use
55513-0488-02 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0488-24 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0488-96 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0478-01 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0478-10 55513-0478 Epoetin alfa Epogen 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous March 3, 1997 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0283-01 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0283-10 55513-0283 Epoetin alfa Epogen 10000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 5, 1994 In Use
55513-0267-01 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0267-10 55513-0267 Epoetin alfa Epogen 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous April 30, 1990 In Use
55513-0224-01 55513-0224 rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0209-01 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-10 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0209-91 55513-0209 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Oct. 2, 2000 In Use
55513-0207-01 55513-0207 Bevacizumab-awwb MVASI 400.0 mg/16mL, 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous June 1, 2018 In Use

Found 10,000 results in 8 millisecondsExport these results